Dr Xu Reviews Data from the CLEAR Trial and Recent Analyses at ASCO 2024 - Lenvatinib + Pembrolizumab in Frontline Advanced RCC

Author(s):

Pedro Barata, MD, MSc,Martin H. Voss, MD

Wenxin (Vincent) Xu, MD, reviews recent analyses from the CLEAR study, which evaluated the combination of lenvatinib and pembrolizumab as a frontline treatment for advanced renal cell carcinoma (RCC).

EP: 1.Treatment Selection in the Frontline Setting of Advanced Clear Cell RCC

EP: 2.Dr Wulff-Burchfield Reviews CheckMate 214 and CheckMate 9ER

Now Viewing

EP: 3.Dr Xu Reviews Data from the CLEAR Trial and Recent Analyses at ASCO 2024 - Lenvatinib + Pembrolizumab in Frontline Advanced RCC

EP: 4.Dr Voss Shares Highlights from the COSMIC-313 and LITESPARK-024 Trials

EP: 5.Exciting Data and Trials in Progress from ASCO 2024

EP: 6.Ongoing RCC Clinical Trials that may Impact Practice

EP: 7.Dr Xu Provides Clinical Perspective on the CONTACT-03 Trial Outcomes

EP: 8.Dr Voss Application of Updated KEYNOTE-564 Data

EP: 9.Guiding Sequencing & Finding a Contemporary Regimen/ Approach to Treatment Post-Checkpoint Inhibition

EP: 10.World Health Organization (WHO) Classification Updates for Papillary RCC

EP: 11.Additional Forward-Looking Data and Studies Beyond Frontline Therapy in RCC

EP: 12.The Role of Chemotherapy in nccRCC Treatment

EP: 13.Select Ongoing Trials for nccRCC and Impact on the Treatment Landscape

EP: 14.Final Thoughts/Looking Forward

Please discuss recent analyses from the CLEAR study, evaluating lenvatinib + pembro in frontline advanced RCC.
1. Efficacy by baseline tumor size (Grunwald, et al. ASCO GU 2024. Abstract 364)
2. Biomarker analysis (Motzer et al. ASCO 2024 Abstract 4504)
3. Network meta-analysis– len + pembro vs other 1L treatments in advanced RCC (Grunwald, et al. ASCO GU 2024. Abstract 482)